Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5954192 | 0.99 | UTS2R (0.84) | UTS2R | |
| SCHEMBL5954681 | 0.91 | UTS2R (0.80) | UTS2R | |
| Hydrochloric Acid SCHEMBL5954576 | 0.90 | UTS2R (0.82) | UTS2R | |
| SCHEMBL4794741 | 0.90 | UTS2R (1.00) | UTS2R | |
| SCHEMBL11582318 | 0.90 | UTS2R (0.78) | UTS2R | |
| SCHEMBL5954022 | 0.89 | UTS2R (1.00) | UTS2R | |
| Hydrochloric Acid SCHEMBL5954508 | 0.88 | UTS2R (0.98) | UTS2R | |
| SCHEMBL5954623 | 0.88 | UTS2R (0.81) | UTS2R | |
| SCHEMBL11582306 | 0.87 | UTS2R (0.63) | UTS2R | |
| SCHEMBL5954186 | 0.87 | UTS2R (0.76) | UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058374-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS INC. | 2006-03-16 | — | — | US | claimed |
| US-20040077529-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2003104216-A1 | UROTENSIN II RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2003-12-18 | — | — | WO | claimed |
| US-20060058374-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS INC. | 2006-03-16 | — | — | US | disclosed |
| US-20040077529-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003104216-A1 | UROTENSIN II RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-4083997-A | ANTIDEPRESSANTS | SANDOZ, INC. (US) | 1978-04-11 | — | — | US | disclosed |
| US-3994961-A | ANTIDEPRESSANTS | SANDOZ, INC. (US) | 1976-11-30 | — | — | US | disclosed |
| US-3880885-A | Tertiary aminoethyl isochromans and isocoumarins | SANDOZ AG | 1975-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077529-A1 | Urotensin II receptor agents | UTS2R, PLAUR, GPR17 | UTS2R 1/4885 |
| US-20060058374-A1 | Urotensin II receptor agents | UTS2R, PLAUR, SCTR | UTS2R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.